SMYD5 and neoplasm: Collectively, these results demonstrate that the combined inhibition of SMYD5 and BRD4 not only synergistically suppresses migration and invasion, but also promotes apoptosis in Hep3B cells, suggesting that targeting SMYD5 may enhance the anti-tumor efficacy of BRD4 inhibition and reduce the metastatic potential of LIHC cells.